


CMS Seeks Comments on Future ASC Prior Authorization Demonstration



Healthcare Law Update

Bill Reintroduced to Track Rising Prescription Drug Prices

Isabelle Bibet-Kalinyak
Vice Chair & Member, Healthcare

Edward Hilzenrath
Member, Healthcare

Erika R. Marshall
Associate, Healthcare

BRACH | EICHLER^{LLC}
Counsellors at Law

2/28/2024

[Assembly Bill 1646](#), reintroduced in the New Jersey General Assembly on January 9, 2024, would establish disclosure requirements regarding prescription drugs and biological product costs. Pharmacy Benefits Managers (PBMs) would be required to disclose information regarding pricing to benefit plan purchasers. PBMs would be required to establish a toll-free telephone number for consumers and pharmacists to use to inquire about plan coverage, pricing, and product safety. Callers would not be permitted to be placed on hold for more than 5 minutes and concerns would need to be resolved within 24 hours. The Bill would establish the Prescription Drug and Biological Product Review Commission. This Commission would have authority to establish a maximum price for drugs or biological products.

[Click Here to read the entire February 2024 Healthcare Law Update now!](#)

For more information, contact:

John D. Fanburg, Chair | 973.403.3107 | jfanburg@bracheichler.com

Edward Hilzenrath | 973.403.3114 | ehilzenrath@bracheichler.com

Erika R. Marshall | 973.364.5236 | emarshall@bracheichler.com